Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)
Current status– finished recruitment – in follow-up.
TRIDENT is an international medical research study which aims to determine the effect of more intensive blood pressure control to prevent recurrent stroke in patients who have had an intracerebral haemorrhage (ICH) (a stroke caused by ruptured blood vessel in the brain). The aim of this project is to test the superiority of a fixed low-dose combination blood pressure-lowering pill (Triple Pill) strategy in recurrent stroke in patients with a history of ICH.
Acute ICH accounts for at least 10% of the 20 million new strokes in the world each year. ICH survivors are at high risk of recurrent stroke and other serious cardiovascular events. Numerous studies have proven the benefit of stroke survivors reducing their risk of recurrent stroke through taking blood pressure-lowering medications. However, studies have shown that many ICH survivors are either not receiving any blood pressure-lowering medication or they are receiving inadequate control.
The TRIDENT study is being conducted in Australia, Brazil, Georgia, Malaysia, Nigeria, The Netherlands, Singapore, Sri Lanka, Taiwan, The UK.
TRIDENT Team Members:
- Professor Craig Anderson – Co-Principal Investigator
- Professor Clara Chow – Co-Principal Investigator
- Professor John Chalmers – Co-Principal Investigator
- Ruth Freed – Global Project Manager
- Cheryl Carcel – Clinical Research Fellow
- Natalie Espinosa – Project Manager
- Lauren Kuhles – Associate Program Manager
- Shalomi Weerawardena – Senior Clinical Research Associate
- Hazel Boge – Project Officer
- Ewelina Czajkowska – Clinical Research Associate
- Troy Colgar – Clinical Trials Associate
